Section of Plastic and Reconstructive Surgery, Department of Surgery Yale University School of Medicine, New Haven, CT, USA.
Division of Plastic and Reconstructive Surgery, Memorial Sloan Kettering Cancer Center New York, NY, USA.
Surg Oncol. 2021 Dec;39:101661. doi: 10.1016/j.suronc.2021.101661. Epub 2021 Sep 13.
Autologous breast reconstruction has evolved from more morbid procedures that sacrificed the abdominal muscle (the TRAM or transverse rectus abdominus muscle flap) to "perforator" flaps. Commercial insurers recognized the higher technical demand of perforator flaps by creating procedural codes with higher professional fees. This study examined whether procedure code discrepancies between insurance payers disproportionally incentivize perforator flaps among the commercially insured.
Autologous breast reconstructions identified from the National Inpatient Sample (NIS) were subdivided into microvascular perforator (85.74, 85.75, 85.76), microvascular TRAM (85.73), and pedicled TRAM flaps (85.72). Demographics, comorbidities and access to care were compared. A logistic regression comparing microvascular reconstructions only was used to identify predictors for perforator flap reconstruction.
A total of 66,968 cases of autologous breast reconstruction were identified. Perforator flaps were more likely among the commercially insured (p < 0.001) and higher insurance quartiles (p < 0.001).When comparing microvascular reconstruction, perforator flaps were 1.72 (p < 0.001) times more likely among the commercially insured. As compared to the lowest income quartile, the fourth quartile had an odds ratio of 1.36 (p < 0.001) for perforator flap reconstruction.
The presence of a separate perforator flap billing code among the commercially insured may be exacerbating existing socioeconomic disparities in breast cancer reconstruction.
自体乳房重建已经从牺牲腹部肌肉(TRAM 或横行腹直肌肌皮瓣)的更病态手术演变为“穿支”皮瓣。商业保险公司通过创建具有更高专业费用的程序代码,认识到穿支皮瓣的更高技术需求。本研究检查了保险支付者之间的程序代码差异是否不成比例地激励商业保险中的穿支皮瓣。
从国家住院样本(NIS)中确定的自体乳房重建分为微血管穿支(85.74、85.75、85.76)、微血管 TRAM(85.73)和带蒂 TRAM 皮瓣(85.72)。比较人口统计学、合并症和获得护理的情况。使用比较微血管重建的逻辑回归来确定穿支皮瓣重建的预测因素。
共确定了 66968 例自体乳房重建病例。穿支皮瓣在商业保险中更常见(p<0.001),并且在更高的保险四分位数中更常见(p<0.001)。在比较微血管重建时,商业保险中的穿支皮瓣更常见 1.72 倍(p<0.001)。与收入最低的四分位数相比,第四四分位数的穿支皮瓣重建比值比为 1.36(p<0.001)。
商业保险中存在单独的穿支皮瓣计费代码可能会加剧乳腺癌重建中现有的社会经济差异。